Streetbeat News

Revenues

EXPD

Analysts have provided varying ratings for Expeditors Intl (NYSE:EXPD) over the last quarter, with a consensus of 'Somewhat Bearish' over the past 30 days. The average 12-month price target is $103.8, down from the previous $105.60. Analysts from firms including JP Morgan and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Expeditors Intl, a non-asset-based logistics provider, has seen a significant revenue decline of -49.8% as of September 30, 2023, but maintains strong net margin and ROE figures.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 8:00 pm

MBUU

Malibu Boats (NASDAQ:MBUU) has received mixed ratings from 5 analysts in the past three months, with 3 bullish and 2 somewhat bullish ratings. The average 12-month price target is now $57.0, down from $60.40, with a high estimate of $62.00 and a low of $50.00. Analysts from Truist Securities, Raymond James, and Keybanc have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Malibu Boats is a leading boat manufacturer with recent acquisitions and in-house engine production. Despite a -15.35% revenue decline as of September 30, 2023, the company has strong financial health indicators such as a 7.92% net margin and a 3.3% ROE.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 8:00 pm

HZO

MarineMax (NYSE:HZO) received mixed analyst ratings over the past three months, with 4 analysts providing ratings. The average 12-month price target is $42.75, with a high of $45.00 and a low of $40.00, marking a 2.84% decrease from the previous average. Analysts from Truist Securities and Stifel have adjusted their price targets and ratings, reflecting their latest views on the company's performance. MarineMax, a U.S.-based recreational boat seller, has shown strong financial performance with a revenue growth rate of 10.77%, a net margin of 2.55%, an ROE of 1.67%, and an ROA of 0.63%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 8:00 pm

WBD

Warner Bros Discovery Inc's (NASDAQ:WBD) 'Hogwarts Legacy' has sold 22 million copies in 2023, potentially becoming the best-selling game of the year. The game's success is notable as it may be the first time since 2009 that neither a Call of Duty nor a Rockstar game has topped the annual sales chart. Warner Bros. Interactive Entertainment is exploring further Harry Potter-themed projects, including a Quidditch game.

Portfolio Pulse from Franca Quarneti

January 09, 2024 | 7:37 pm

EA

RBLX

TTWO

BMO Capital Markets released an industry primer with a positive outlook for the gaming sector in 2024, highlighting the growth potential of megahit titles and the expanding console market. The report emphasizes the importance of owning franchises like Electronic Arts Inc's EA Sports FC, Take-Two Interactive Software Inc's Grand Theft Auto, and Roblox Corp's Roblox, citing their strong positions and potential for revenue growth. The gaming industry has seen revenues double to $193 billion in 2023, with 3.4 billion gamers globally. BMO projects robust growth in the console market, particularly in the U.S., and recommends investing in companies with significant console game revenue like EA and Take-Two. The report also notes the evolution of business models and the dominance of megahit titles as key investment drivers. Roblox is highlighted for its unique platform and user retention beyond age 13, with expectations of improved monetization and cash flows.

Portfolio Pulse from Franca Quarneti

January 09, 2024 | 7:18 pm

AMAM

Ambrx Biopharma (NASDAQ:AMAM) has been rated by 7 analysts in the last three months, with 5 somewhat bullish and 2 indifferent ratings. The average 12-month price target is $22.43, down 8.45% from the previous $24.50. Analysts from B. Riley Securities, JMP Securities, Goldman Sachs, RBC Capital, and Cantor Fitzgerald have updated their ratings and price targets. Ambrx Biopharma is a clinical-stage biologics company with a declining revenue growth of -96.68% as of September 30, 2023, and a net margin of -43375.47%. The company's ROE is -9.33% and ROA is -8.34%, with a debt-to-equity ratio of 0.04.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 7:01 pm

C

Analysts have provided mixed reviews on Citigroup (NYSE:C) over the last three months, with recent ratings ranging from bullish to indifferent. The average 12-month price target is $62.11, with a high of $85.00 and a low of $45.00. Citigroup's financial performance shows strong revenue growth but challenges in profitability, debt management, and returns on equity and assets. Analysts' actions include both upgrades and downgrades, reflecting their ongoing assessment of the company's market conditions and performance.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 7:00 pm

ACCD

CUTR

GRFS

HPE

JNPR

NEOG

SNX

TCS

U.S. stocks were mostly lower, with the Dow Jones down 0.49%. TD SYNNEX Corporation (NYSE:SNX) reported lower Q4 sales but beat EPS estimates and provided Q1 2024 guidance below expectations. Crude oil prices rose by 2.4%. Cutera, Inc. (NASDAQ:CUTR) and Accolade, Inc. (NASDAQ:ACCD) saw stock prices surge after positive financial updates, while Grifols, S.A. (NASDAQ:GRFS) and Neogen Corporation (NASDAQ:NEOG) fell sharply due to negative reports. Juniper Networks, Inc. (NYSE:JNPR) spiked on acquisition talks with Hewlett Packard Enterprise Co (NYSE:HPE). The Container Store Group, Inc. (NYSE:TCS) dropped after projecting lower-than-expected sales.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 6:08 pm

NVO

Novo Nordisk's CEO predicts a 'significantly higher stay time' for patients using Wegovy for obesity treatment, indicating increased duration of use compared to current treatments.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:04 pm

IAS

Four financial analysts have recently updated their ratings for Integral Ad Science (NASDAQ:IAS), with three being somewhat bullish and one indifferent. The average 12-month price target is now $17.38, down from $21.83, indicating a 20.38% decrease. Analysts from BMO Capital, Piper Sandler, Morgan Stanley, and Barclays have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Integral Ad Science, a digital ad verification company, has seen a revenue growth of 18.74% over the past three months but struggles with profitability and efficiency, with a net margin of -11.43% and ROE of -1.57%.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:01 pm